Search Results
10
Everything
Search Filters
Organization
FibroGen, Inc.
FibroGen Announces Publication of Results from Phase 1 Monotherapy Study of FG-3246 in Patients with Metastatic Castration-Resistant Prostate Cancer in the Journal of Clinical Oncology
March 28, 2025 07:00 ET
|
FibroGen, Inc.
FG-3246 showed encouraging anti-cancer activity with an acceptable safety profile in patients with metastatic castration-resistant prostate cancerInitiation of Phase 2 monotherapy dose optimization...
FibroGen Reports Fourth Quarter and Full Year 2024 Financial Results
March 17, 2025 16:05 ET
|
FibroGen, Inc.
Announced sale of FibroGen China to AstraZeneca for a total consideration of approximately $160 million Transaction expected to close by mid-2025 Upon close of sale of FibroGen China, cash runway...
FibroGen to Report Fourth Quarter and Full Year 2024 Financial Results
March 03, 2025 16:45 ET
|
FibroGen, Inc.
SAN FRANCISCO, March 03, 2025 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) will announce fourth quarter and full year 2024 financial results on Monday, March 17 after the markets close....
FibroGen Announces the Sale of FibroGen China to AstraZeneca for Approximately $160 Million
February 20, 2025 06:30 ET
|
FibroGen, Inc.
Purchase price represents enterprise value of $85 million plus FibroGen net cash held in China at closing, currently estimated to be approximately $75 millionUpon close, FibroGen will repay its term...
FibroGen Appoints David DeLucia as Chief Financial Officer
December 16, 2024 08:05 ET
|
FibroGen, Inc.
SAN FRANCISCO, Dec. 16, 2024 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) today announced the appointment of David DeLucia to Chief Financial Officer (CFO), effective December 16, 2024. The...
FibroGen Reports Third Quarter 2024 Financial Results
November 12, 2024 16:05 ET
|
FibroGen, Inc.
Topline results from Phase 2 portion of the investigator-sponsored study of FG-3246, a first-in-class antibody-drug conjugate (ADC) targeting CD46, in combination with enzalutamide in patients with...
FibroGen to Report Third Quarter 2024 Financial Results
November 04, 2024 16:05 ET
|
FibroGen, Inc.
SAN FRANCISCO, Nov. 04, 2024 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) will announce third quarter 2024 financial results on Tuesday, November 12 after the market close. FibroGen will also...
FibroGen to Present at the H.C. Wainwright 26th Annual Global Investment Conference
September 03, 2024 16:05 ET
|
FibroGen, Inc.
SAN FRANCISCO, Sept. 03, 2024 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) today announced that the Company will be attending and presenting at the H.C. Wainwright 26th Annual Global Investment...
FibroGen Reports Second Quarter 2024 Financial Results and Provides Business Update
August 06, 2024 16:05 ET
|
FibroGen, Inc.
Company implementing significant cost reduction plan in the U.S. due to results in late-stage pamrevlumab pancreatic cancer trials, including a reduction of U.S. workforce by approximately 75%Focus...
FibroGen to Report Second Quarter 2024 Financial Results
July 30, 2024 16:07 ET
|
FibroGen, Inc.
SAN FRANCISCO, July 30, 2024 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) will announce second quarter 2024 financial results on Tuesday, August 6 after the market close. FibroGen will also...